A panel of independent FDA advisers is meeting today to consider the merits of Spark Therapeutics’ (ONCE) Luxturna, a one-time gene therapy meant to treat a rare, inherited form of childhood blindness.
If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn’t disclosed pricing, but analysts estimate Luxturna could cost $1 million or more per patient, a price that might force payers and insurers to rethink their coverage and reimbursement models.
STAT’s Adam Feuerstein is watching Thursday’s Luxturna advisory panel and will be posting updates throughout the day. STAT Plus subscribers can also tune in at 3:30 pm ET for a live chat in which Adam and Damian Garde will break down the panel’s vote and take your questions. You can read a preview of today’s Spark FDA panel here.
About the Author Reprints
Interested in gene therapy for STARGARDT disease.
Dharam
281-745-2547
Buenas tardes, quisiera que por favor me ayudaran tengo una sobrina de 38 anos , es sordomuda y tiene sindrome de Usher, retinitis pigmentosa, ha perdido la vision de los lados , este tratamiento pudiera ayudarle a ella, por favor me indican el costo es una persona de muy bajos recursos, se deprime mucho por esta condicion y no se como ayudarla. Gracias por ayudarnos Dios les de mucha sabiduria para que continuen en tan excelente labor.
Rrrttt